ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001

American cancer Society Funds 84 Research Grants. NCI, NIGMS To Support Synchrotron Beamlines.

November 16, 2001

CIDAC Bids Not Limited To Cancer Research Centers

January 17, 1975

NCI CTEP-Approved Trials For the Month of June

June 27, 2014

Prostate Cancer Patient Groups Consider formation Of Coalition Using the “NBCC Model”

August 16, 1996

In Brief: Over Half Of Ovarian Cancer Patients Staged Incorrectly; Senate Gets Funding Resolution

April 12, 1985